Clinical and laboratory manifestations in patients with PHAPS and in controls. Except for p values, data are n (%).
| PHAPS, n = 13 | Controls, n = 50 | p | |
|---|---|---|---|
| Sex, women | 8 (61) | 40 (80) | 0.14 |
| Mitral valve disease | 9 (75) | 11 (22) | 0.001 |
| CNS disease | 8 (61) | 8 (16) | 0.001 |
| Pregnancy morbidity* | 7 (87.5) | 13 (32.5) | 0.005 |
| Skin involvement | 7 (54) | 4 (8) | 0.001 |
| Pulmonary hypertension | 9 (75) | 5 (22) | 0.004 |
| Low C3 | 1 (8) | 6 (18) | 0.65 |
| Low C4 | 7 (54) | 13 (44) | 0.03 |
| Lupus anticoagulant | 10 (91) | 38 (97) | 0.39 |
| High β2-GPI IgG | 10 (83) | 8 (30) | < 0.001 |
| High-titer aCL IgG | 12 (92) | 21 (43) | 0.002 |
↵* Percentage among women. PHAPS: pulmonary hemorrhage and antiphospholipid antibody syndrome; CNS: central nervous system; GPI: glycoprotein I; aCL: anticardiolipin; IgG: immunoglobulin.